Phase III trials of Pfizer’s mRNA-based influenza vaccine begin
Leveraging their current mRNA vaccine technology developed during the COVID-19 pandemic, Pfizer have announced the start of phase III trials for a potential mRNA-based influenza vaccine.
Pfizer has announced that it has started late-stage trials in the United States for their influenza vaccine utilising mRNA technology based on the same principles as their COVID-19 vaccine developed with BioNTech, with a study involving 25,000 patients.
Influenza is responsible for approximately 12,000–52,000 deaths in the United States alone every year. With different viral strains emerging each year, vaccines must continuously evolve and change to continue providing protection. Current vaccine technology relies on the growth of viruses in a culture, and killed with specific chemicals, producing inactivated vaccines. This process may require months to produce a viable vaccine. Even when currently available vaccine strains match that year’s circulating influenza strains, such vaccines may only provide 40%-60% protection. Predicting the next influenza season’s strain is a constant battle for global health experts and researchers.
mRNA technology could allow future vaccine strains to change faster. Pfizer expects this flexibility, along with rapid manufacturing, to provide better strain matches in the future. In a potential pandemic situation, mRNA vaccines may allow for large-scale manufacturing of vaccines as they only require the genetic sequence of a virus. Pfizer’s mRNA vaccine is known as a modRNA vaccine, encoded with recommended strains for the Northern Hemisphere 2022–2023 cell culture- and recombinant-based influenza vaccines. Continuing from the phase II trials demonstrating safety and immunogenicity profiles, the phase III trial will focus on leveraging the mRNA technology in a vaccine to protect against more than the flu. The mRNA technology developed by Pfizer will be investigated for other applications outside the modRNA vaccine candidate.
Annaliesa Anderson, Senior VP And CSO, Vaccine Research and Development at Pfizer, stated: “For years, there has been a need to better address the burden of influenza, despite the use of existing seasonal flu vaccines. Our experience with RNA viruses and mRNA technology has given us an even deeper understanding of the opportunity to potentially provide more efficacious vaccines that could further reduce the yearly rates of the sever outcomes of viral disease like flu, including hospitalisation and death... We are excited to start the first phase III efficacy study of an mRNA-based influenza vaccine that could potentially deliver an improved flu vaccine to help address the significant burden of this disease.”
Source: Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine | Pfizer
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance